Methodologies and tools to shed light on erythrophagocytosis

Turpin, Chloé; Meilhac, Olivier; Bourdon, Emmanuel; Canonne‐Hergaux, François; Rondeau, Philippe

doi:10.1016/j.biochi.2022.07.017

Cited by 5 publications

(3 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 37 ] Opsonins are protein molecules that bind to foreign particles or antigens entering the body and facilitate their recognition by the immune system. [ 38 ] This process of binding opsonins with antigens to render them recognizable by the phagocytic cells is known as opsonization. Hence, scientists have developed techniques to shield nanoparticles from the body's protective mechanisms.…”

Section: Resultsmentioning

confidence: 99%

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Miraghaie,

Zandi,

Davari

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

Pure positive electrostatic charges (PPECs) show suppressive effect on the proliferation and metabolism of invasive cancer cells without affecting normal tissues. PPECs are used for the delivery of drug‐loaded polymeric nanoparticles (DLNs) capped with negatively charged poly(lactide‐co‐glycolide) (PLGA) and Poly(vinyl‐alcohol) PVA into the tumor site of mouse models. The charged patch is installed on top of the skin in the mouse models' tumor region, and the controlled selective release of the drug is assayed by biochemical, radiological, and histological experiments on both tumorized models and normal rats' livers. It is found that DLNs synthesized by PLGA show great attraction to PPECs due to their stable negative charges, which would not degrade immediately in blood. The burst and drug release after less than 48h of this synthesized DLNs are 10% and 50%, respectively. These compounds can deliver the loaded‐drug into the tumor site with the assistance of PPECs, and the targeted‐retarded release will take place. Hence, local therapy can be achieved with much lower drug concentration (conventional chemotherapy [2 mg kg−1] versus DLNs‐based chemotherapy [0.75 mg kg−1]) with negligible side effects in non‐targeted organs. PPECs have many potential clinical applications for advanced‐targeted chemotherapy with the lowest discernible side effects.

show abstract

Section: Resultsmentioning

confidence: 99%

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Miraghaie,

Zandi,

Davari

et al. 2023

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…Eryptosis has been described as an apoptosis-like protective process to eliminate abnormal and/or dysfunctional erythrocytes negatively affected, e.g., by oxidative stress, hyperosmotic conditions, ATP shortage, or exposure to toxic compounds and xenobiotics (Pretorius et al, 2016;Alghareeb et al, 2023). Rapid removal of eryptotic erythrocytes is carried out by macrophages through PS-mediated phagocytosis (Chang et al, 2018;Turpin et al, 2022).…”

Section: Brief Overview Of Eryptosismentioning

confidence: 99%

Redox Status of Erythrocytes as an Important Factor in Eryptosis and Erythronecroptosis

Tkachenko,

Havránek

2023

Fol. Biol.

View full text Add to dashboard Cite

Overall, reactive oxygen species (ROS) signalling significantly contributes to initiation and modulation of multiple regulated cell death (RCD) pathways. Lately, more information has become available about RCD modalities of erythrocytes, including the role of ROS. ROS accumulation has therefore been increasingly recognized as a critical factor involved in eryptosis (apoptosis of erythrocytes) and erythronecroptosis (necroptosis of erythrocytes). Eryptosis is a Ca2+-dependent apoptosis-like RCD of erythrocytes that occurs in response to oxidative stress, hyperosmolarity, ATP depletion, and a wide range of xenobiotics. Moreover, eryptosis seems to be involved in the pathogenesis of multiple human diseases and pathological processes. Several studies have reported that erythrocytes can also undergo necroptosis, a lytic RIPK1/RIPK3/MLKL-mediated RCD. As an example, erythronecroptosis can occur in response to CD59-specific pore-forming toxins. We have systematically summarized available studies regarding the involvement of ROS and oxidative stress in these two distinct RCDs of erythrocytes. We have focused specifically on cellular signalling pathways involved in ROS-mediated cell death decisions in erythrocytes. Furthermore, we have summarized dysregulation of related erythrocytic antioxidant defence systems. The general concept of the ROS role in eryptotic and necroptotic cell death pathways in erythrocytes seems to be established. However, further studies are required to uncover the complex role of ROS in the crosstalk and interplay between the survival and RCDs of erythrocytes.

show abstract

“…Daily, 1 -2 mg of iron is absorbed in the intestine, but the same amount is released by the exfoliation of the mucous membrane. The most significant amount of the iron (20 -25 mg/day) derives by erythrophagocytosis from the discharge of iron deriving from senescent erythrocytes recycled by Kupffer cells and macrophages from the spleen [1] [2] [3] [4] [5].…”

Section: Introductionmentioning

confidence: 99%

Iron and Heart Failure: Current Concepts and Emerging Pharmacological Paradigms

Pascale,

Rondinelli,

Ascione

et al. 2024

WJCD

View full text Add to dashboard Cite

Background: Emerging evidence has recognized that anemia and iron deficiency are recurrent comorbidities in chronic heart failure (HF) and several trials have established that iron administration improves myocardial asset and clinical scenario in HF. Purpose: Recent acquisitions suggest that iron deficiency represents a concrete bias in the pathogenetic mechanism of chronic HF, so we have investigated the putative role of the hepcidin/ferroportin axis in the cardiovascular setting to advocate novel pharmacological and clinical approaches. Methods: Here, after an excursus on iron metabolism, we first reviewed the ongoing studies on novel iron targeted compounds. Then, we summarize large clinical interventional studies conducted on patient suffering from iron deficiency and HF which have tested the effects of drugging iron regard QoL, hospitalizations and cardiovascular death. Results: Novel compounds such as hepcidin agonist (PTG 300), synthetic human hepcidin (LJPC-401) and anti FPN (Vamifeport) are ongoing in iron overloaded patients, while the hepcidin blocker (PRS-080) is under investigation in anemic patients. Noteworthy, novel insights could arise from the results of a Phase IV interventional study regarding the modification of hepcidin pathway in a large cohort of HF patients (n = 1992) by sodium glucose cotransporter 2 inhibitors. To date, several studies highlight the beneficial effect of iron administration in cardiovascular setting and latest evidences consider hepcidin level as a novel biomarker of cardiac injury and atherosclerosis. Conclusions: We advocate that data from ongoing studies will suggest novel iron targeted

show abstract

Methodologies and tools to shed light on erythrophagocytosis

Cited by 5 publications

References 116 publications

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Targeted Delivery of Anticancer Drug Loaded Charged PLGA Polymeric Nanoparticles Using Electrostatic Field

Redox Status of Erythrocytes as an Important Factor in Eryptosis and Erythronecroptosis

Iron and Heart Failure: Current Concepts and Emerging Pharmacological Paradigms

Contact Info

Product

Resources

About